The local lymph node assay (LLNA) is used to test the potential of low molecular weight (LMW) compounds to induce sensitization via the skin. In the present study, a respiratory LLNA was developed. Male BALB/c mice were exposed head/nose-only during three consecutive days for 45, 90, 180, or 360 min/day to various LMW allergens. Ear application (skin LLNA) was used as a positive control. Negative controls were exposed to the vehicle. Three days after the last exposure, proliferation was determined in the draining mandibular lymph nodes, and the respiratory tract was examined microscopically. Upon inhalation, the allergens trimellitic anhydride, phthalic anhydride, hexamethylene diisocyanate, toluene diisocyanate, isophorone diisocyanate (IPDI), dinitrochlorobenzene, and oxazolone were positive and showed stimulation indices (SIs) up to 11, whereas trimeric IPDI, formaldehyde, and methyl salicylate were negative (viz. SI < 3). All compounds, except trimeric IPDI, induced histopathological lesions predominantly in the upper respiratory tract. Exposure by inhalation is a realistic approach to test respiratory allergens. However, based on the local toxicity, the dose that can be applied is (generally) much lower than can be achieved by skin application. It is concluded that strong LMW allergens, regardless their immunological nature, besides the skin can also sensitize the body via the respiratory tract. In addition, the contact allergens were as potent as the respiratory allergens, although the potency ranking differed from that in a skin LLNA.
The local lymph node assay (LLNA) is designed to monitor cellular proliferation, as measured by the uptake of tritiumthymidine ([ 3 H]TdR) by the draining lymph node (LN) cells, in order to assess the potential of compounds to induce sensitization via the skin (Kimber and Weisenberger, 1989; Kimber et al., 1994) . Chemicals that elicit a stimulation index (SI) of 3 or more-a threefold increase in [
3 H]TdR incorporation relative to the control value-in the LLNA are considered skin sensitizers. The EC 3 value being the dose (concentration) inducing stimulation rates of threefold of the control values has been suggested to be used as an indicator of the potency of skin sensitization (Kimber et al., 1995; Loveless et al., 1996) . Based on the EC 3 value, chemicals can be ranked and selected for low skin sensitizing potency Van Och et al., 2000) . Within the context of REACH, the LLNA is the preferred assay to investigate skin sensitization potential (EC, 2006) .
There is evidence that most, if not all, low molecular weight (LMW) respiratory allergens also test positive in the dermal LLNA or other assays for skin sensitization such as the guinea pig maximization or Buehler test (Arts, 2001; Kimber et al., 2007; Van Loveren et al., 2008) , and thus, would require labeling for sensitization via the skin (Risk Phrase 43). There are at present no validated assays to test for the potential of compounds to sensitize by inhalation, that is, via the respiratory tract (Risk Phrase 42). Can it be expected that sensitization mechanisms for the skin are similar to the sensitization mechanisms for the respiratory tract? Potential and potency may differ between these two routes because the respiratory epithelium has a less robust mechanical defense than skin and antigen-presenting and immune-regulating mechanisms may be different. To test if an inhalation exposure to allergens could induce proliferation in the LNs, which drain the respiratory tract, and, if so, to test whether potency would be comparable for the inhalation route and dermal route, a so-called respiratory LLNA was developed. The test compounds were known respiratory allergens including trimellitic anhydride (TMA), phthalic anhydride (PA), toluene diisocyanate (TDI), hexamethylene diisocyanate (HDI), and isophorone diisocyanate (IPDI) . The responses to these compounds were compared to the responses to the typical contact allergens dinitrochlorobenzene (DNCB), oxazolone (OXA), and formaldehyde (FA) and those of a respiratory irritant methyl salicylate (MS), and a compound of unknown inhalation sensitizing properties namely oligomeric isophorone diisocyanate (trimeric IPDI). The protocol of the respiratory LLNA was identical to the skin LLNA, viz. three days of exposure (days 0, 1, and 2) followed 1 To whom correspondence should be addressed at TNO Quality of Life, Toxicology and Applied Pharmacology, PO Box 360, 3700 AJ Zeist, the Netherlands. Fax: þ31-30-69-44-986. E-mail: frieke.kuper@tno.nl.
by necropsy on day 5 after which the proliferation activity was measured in the draining LNs. During exposure, the concentration was held constant, but exposure duration was varied in order to obtain an increasing exposure dose for each group of animals. The selection of the draining or local LNs upon an inhalation exposure to be used in the respiratory LLNA is less straightforward than upon dermal application in the skin LLNA because there are many LNs draining the respiratory tract (Van den Broeck et al., 2006) . Rather than injecting the animals with radioactive label in vivo, the draining LNs were excised and the LN cells were cultured with radioactive label in vitro. This method was proven to be a good alternative and requires much less radioactive label and waste Kimber and Weisenberger, 1989; Van Och et al., 2000) . The ex-vivo procedure allowed us to also measure the cytokine profiles in the local LNs, thus offering an opportunity to reduce the number of animals which is needed in separate LLNA and cytokine assays. The cytokine data will be reported separately (De Jong, Wim H. de Jong, Josje H.E. Arts, Arja de Klerk, Marcel A. Schijf, Janine Ezendam, C. Frieke Kuper, H. van Loveren, submitted).
The present paper describes the performance (sensitization potential and potency) of a selection of LMW allergens in a respiratory LLNA and compares these with data obtained in simultaneously and previously conducted skin LLNAs.
MATERIALS AND METHODS
Animals and maintenance. Male, 6-to 7-week-old, inbred BALB/c mice were purchased from Charles River Deutschland (Sulzfeld, Germany) and acclimatized for at least 5 days before the start of each experiment. They were kept under conventional laboratory conditions and received the standard pelleted diet (RM3 [E] SQC, Special Diet Service, Witham, UK) and unfluoridated tap water ad libitum. All animal procedures were approved by the Institute's Commission of Animal Welfare.
Chemicals. The following chemicals were used: TMA (97% purity), toluene 2,4-diisocyanate (TDI; technical grade, 80%), and hexamethylene-1,6-diisocyanate (HDI; 98% purity; all from Aldrich, Brussels, Belgium); 2,4-dinitrochlorobenzene (DNCB; purity at least 98%), OXA (4-ethoxymethylene-2-phenyl-2-oxazolin-5-one; purity at least 90%), MS (purity at least 99%), and raffinated olive oil (all from Sigma, St Louis, MO); PA (purity at least 99%) and FA (pro analysis purity at least 36.5% in H 2 O); both from Fluka, Buchs, Switzerland); monomeric and oligomeric IPDI (Degussa GmbH, Marl, Germany; acetone (from Biosolve, Valkenswaard, the Netherlands). Oligomeric IPDI consisted of 67% of trimeric IPDI (the remaining consisted of pentameric, heptameric, and nonameric IPDI) and is therefore called trimeric IPDI during the remainder of the paper.
Experimental design. Groups of male BALB/c mice (six animals per group) were exposed nose-only to one of the various LMW compounds for 45, 90, 180, or 360 min/day on three consecutive days. The dermal route (ear application) was used as a positive control. Negative controls were exposed by ear application of the vehicle (acetone-olive oil, 4:1) or by inhalation to the vehicle (acetone or air) for 360 min/day for 3 days. The animals were necropsied 3 days after the last exposure, several draining LNs were excised, LN cells were harvested, and DNA was labeled with [ 3 H]-thymidine to determine proliferation. In the positive, dermally exposed control group, the auricular LNs were excised. In addition, the respiratory tract was histopathologically examined, and cytokine production in the cultured draining LN cells was measured using a Bio-Plex assay (Biorad Laboratories, Hercules, CA). The results of the cytokine examinations will be reported separately (De Jong et al., submitted) .
Dermal exposure. Animals received 25 ll/day of a single concentration of each test substance, dissolved in a 4:1 (vol/vol) mixture of acetone and olive oil (AOO) on the dorsum of both ears on three consecutive days (positive skin control), or AOO alone (negative skin control). Target concentrations of the various test chemicals as well as controls and numbers of animals are summarized in Table 1 . The target concentrations of DNCB, OXA, PA, TDI, and TMA were based on dermal LLNAs, previously performed in BALB/c mice (Van Och et al., 2000) . 
AOO (3)
Inhalation exposure and test atmosphere generation and analysis. Mice were exposed to one of the various test materials on three consecutive days for 45, 90, 180, or 360 min/day. Variation in exposure duration rather than in concentration was used to investigate the dose-response relationships. The target concentrations of TMA, TDI, DNCB, and OXA were based on previous inhalation experiments (Arts et al., 1998 (Arts et al., , 2004 Mommers et al., 2006; or unpublished results) .
During exposure, the mice were individually restrained in Battelle tubes, and each tube was then placed into inhalation units (ADG Developments Ltd., Codicote, Herts, UK) for head/nose-only exposure to the test atmosphere. The units had a volume of approximately 50 l. Exposure air flows were at least 0.3 l/ min per animal. DNCB, TMA, OXA, PA, and IPDI (monomer and trimer) test atmospheres were generated as aerosols from daily freshly prepared solutions of the chemicals in acetone. Acetone was used to help generate respirable particles of these compounds normally consisting of very large noninhalable particles. The solutions were delivered to a compressed air-driven nebulizer (Schlick type 970/S, Coburg, Germany) by a motor-driven syringe pump (WPI type SP22i, World Precision Instruments, Sarasota, FL). Air flow to the nebulizer was regulated by a mass flow controller (Bronkhorst Hi Tec, Ruurlo, the Netherlands). The aerosolized acetone evaporated completely before reaching the animals nose. The final acetone concentrations in air were below 600 ppm (1.4 g/m 3 ; viz. below 0.06% in air; Table 2 ), which is considered to be far below a level inducing sensory irritation (Alarie, 1973; De Ceaurriz et al., 1981; Schaper and Brost, 1991) . The corresponding controls were exposed to similar low levels of acetone in air for 360 min/day (Table 2 ). Test atmospheres of the more volatile substances TDI, HDI, MS, and FA were generated by evaporation. The chemicals were delivered to a glass evaporator by a motordriven syringe pump (WPI type SP22i, World Precision Instruments). The temperature in the evaporator was controlled by circulating heated water (at 60°C and 70°C, in case of TDI and HDI, and of MS and FA, respectively). The corresponding controls were exposed to clean air only for 360 min/day. Thus, test atmospheres, except for the presence of test compound, consisted of air or air with maximally 0.06% acetone, which is a completely different situation when using different vehicles in the dermal LLNA.
The temperature and relative humidity (RH) were recorded during exposure. The mean temperature was 21.6 ± 0.4°C for control atmospheres and 22.0 ± 0.4°C for the test atmospheres. The RH was 42.8 ± 3.7% and 47.5 ± 7.4% for the control and test atmospheres, respectively, except in experiments with the chemically very reactive compounds TDI and HDI where animals were exposed under dry air conditions (mean RH of 3.3 ± 0.8%).
The concentrations of DNCB, TMA, OXA, PA, and trimeric IPDI in the test atmosphere were determined gravimetrically by filter sampling at 5 l/ min. TDI, HDI, and monomeric IPDI concentrations were analyzed according to method MDHS 25/3 (White, 2006) . In short, samples of the test atmosphere (1.0 l/min) were adsorbed onto 1-(2-methoxyphenyl) piperazine-coated glass fiber filters, followed by solvent desorption and analysis using reversed phase high-performance liquid chromatography (RP-HPLC) with UV detection at 242 nm. In addition, the concentrations of TDI, HDI, and MS were monitored using a total carbon analyzer (Ratfisch RS55T, Munich, Germany). The MS concentrations were calculated based on the nominal concentration and the complete evaporation of the test solution. FA concentrations were analyzed according to method MDHS 78. Samples of the test atmosphere (1.5 l/min) were adsorbed onto 2,4-DNPHsilica cartridges (Waters Chromatography, Etten-Leur, the Netherlands), followed by solvent desorption, and RP-HPLC analysis with UV detection at 365 nm. Actual concentrations are indicated in Table 2 ; these were close to the target concentrations.
Particle size distributions of DNCB, OXA, TMA, PA, and trimeric IPDI in the test atmospheres were determined using a 10-stage cascade impactor (Andersen, Atlanta, GA). The mass median aerodynamic diameter (MMAD) and geometric standard deviations of these chemicals are depicted in Table 2 . The particle size measurements indicated that aerosol particles were of respirable size. The other compounds (TDI, HDI, IPDI, MS, and FA) were present in the gaseous phase, and therefore no particles were present.
Local effects, body and organ weights, and necropsy. All animals were observed at least once daily and weighed shortly before the first treatment and just prior to necropsy. At necropsy, 5 days after the first exposure, animals were anesthetized with Nembutal, killed by exsanguination from the abdominal aorta, and examined grossly for abnormalities. Draining LNs were excised, and the nose and lungs with trachea and larynx were removed. The lungs (with trachea and larynx) were weighed in case of TMA, PA, TDI, DNCB, and OXA exposure.
Local LN activation. The pulmonary and dermal sensitizing potency of the chemicals was investigated in a modified LLNA using ex vivo labeling of the proliferating LN cells Kimber and Weisenberger, 1989; Vandebriel et al., 2000; Van Och et al., 2002) . In a preliminary 3-day test 
Actual concentration was measured 4-8 times per day except for the MS concentration that was calculated over three separate days; mean was given over the 3-day period. Particle size distribution was measured on the first exposure day; -not used; NA, not applicable as no particles were present in the test atmosphere.
RESPIRATORY LOCAL LYMPH NODE ASSAY 425 at a high concentration of 250 mg/m 3 TMA, it was examined which LNs were enlarged. These were, as expected, the auricular LNs upon dermal treatment and, not entirely expected, the mandibular LNs following inhalation exposure. Therefore, these LNs were taken out in all further exposures, and when enlargement of other LNs was noted at macroscopic observation of the highest dosage group, these were collected additionally in all groups. This was especially the case for the cervicalis posterior LNs in animals exposed by inhalation to HDI and IPDI and also for the auricular LNs following inhalation exposure to TDI, HDI, IPDI, and OXA. For a better comparison, the auricular LNs were therefore taken out following all exposures except for DNCB which was the first study.
The cells of left and right LNs were pooled for each animal and suspended in 5 ml RPMI-1640 (Gibco, Life Technologies, Breda, the Netherlands) supplemented with 5% heat-inactivated fetal calf serum (FCS; Integro, Zaandam, the Netherlands), 100 U/ml penicillin, and 100 lg/ml streptomycin (referred to as supplemented medium). Single-cell suspensions were prepared in supplemented medium under aseptic conditions by pressing the LNs through a 70-lm nylon cell strainer (Falcon, Franklin Lakes, NJ). Cells were washed twice (10 min, 300 g, 4°C), resuspended in 1 ml supplemented medium with 10% FCS, and counted using a Coulter Counter (Z2, Coulter Electronics, Mijdrecht, the Netherlands). After counting, the concentration of the cell suspensions was adjusted to 1 3 10 7 cells/ml. When necessary, cell suspensions of a few animals were pooled to obtain concentrations of 1 3 10 7 cells/ml, notably for vehicle-treated controls. To assess lymphocyte proliferation, cell suspensions (2 3 10 6 cells in 200 ll supplemented medium per well) were seeded in triplicate in round-bottomed 96-well microtiter plates (Greiner, Alphen aan de Rijn, the Netherlands (stimulation rates of threefold the control values in relation to the respiratory exposure dose) were derived by plotting SI values against total dose, followed by linear interpolation between two points on the SI axis, immediately above and below SI ¼ 3, similar to the calculation of the EC 3 value after dermal exposure. Subsequently, ED 3 values were calculated using the equation:
where (a, b) and (c, d) represent data points above and below an SI value of 3, respectively (Basketter et al., 1999) .
Airway histopathology. Neutral, phosphate-buffered 4% (vol/vol) FA was used to inflate and preserve the lungs and to preserve the nose and larynx. Next, these organs were embedded in paraffin wax, and 5 lm sections were stained with hematoxylin and eosin. Cross sections of the nasal tissues were prepared at four different levels. The larynx was sectioned longitudinally at three levels including the epiglottis, the ventral pouch, and the arythenoid projections. Each lung lobe was cut at one median sagittal level. All tissues of animals exposed for 360 min/day (high dose group) were examined microscopically. In addition, tissues of all DNCB-exposed animals were examined to investigate dose-response relationships by increasing exposure duration at a constant concentration.
Statistics. SIs in mandibular and auricular LNs following inhalation exposure were statistically analyzed after logarithmic transformation, using a one-way ANOVA, followed by a two-sided Dunnett's test. A p value <0.05 was considered to be statistically significant. First, outliers were detected using Grubb's test and rejected for further analysis.
RESULTS
Local effects, body and organ weights, and necropsy.
The inhalation exposures were relatively well tolerated by the animals, and no abnormalities were noted during each day's exposure. Clinical signs noted after exposure were piloerection and hunched posture (TMA, OXA, PA, TDI), blepharospasm (OXA, PA, IPDI), dyspnoea (TMA, PA), sluggishness (PA), and leanness (TMA; data not shown). One animal exposed to FA (180-min group) and one control animal exposed to clean air (during the study with TDI) died on the first day of exposure, and one animal exposed to OXA (360-min group) died on day 4. The animal exposed to OXA may have died because of the inhaled dose; the FA-exposed death was considered not to be test-compound related, just like the control animal.
Slight to moderate losses in body weight between day 0 and day 5 were seen following exposure to TDI, HDI, and OXA (all four test groups), TMA, PA, and FA (90-, 180-and 360-min exposure groups), DNCB (180-and 360-min exposure groups), and IPDI (360-min exposure group only). No changes in body weights were observed following exposure to trimeric IPDI and MS (data not shown).
Lung weights were determined in animals exposed to DNCB, OXA, TMA, PA, and TDI. Slight to strong increases in relative lung weight were observed at necropsy in animals exposed to DNCB and OXA (all four test groups), TMA and PA (90-, 180-and 360-min exposure groups), and TDI (360-min exposure group only; data not shown). Because mean absolute lung weights were 140-150 mg in almost all groups, the increase in relative lung weight was largely explained by the decrease in body weight.
Findings at necropsy generally consisted of rales (TMA), visually increased breathing rate (TMA, TDI), air-filled intestines (TMA, PA, OXA, TDI), leanness (HDI, IPDI), and stained lungs (IPDI) . No data were available for DNCBexposed animals, and no changes were generally observed in animals exposed to FA, trimeric IPDI, or MS (data not shown). The aforementioned changes generally showed a clear exposure duration-related increase in severity and/or incidence.
Local LN activation.
The mandibular LNs draining the nasal tissues following inhalation exposure to TMA, PA, TDI, HDI, IPDI, DNCB, and OXA were enlarged and showed statistically significant increases in SIs, which were in excess of 3 in many groups. Clear dose (concentration 3 time)-response relationships were obtained for HDI and DNCB, and to a lesser extent for IPDI; bell-shaped curves were seen in the case of TMA, TDI, and OXA. The response to PA, though positive, was variable. No increases were observed following inhalation exposure to FA, trimeric IPDI, and MS (Table 3 and Fig. 1 ).
Highly significant, dose (concentration 3 time)-related increases in SI values (with SI values up to 100) were seen in the auricular LNs following inhalation exposure to TDI, HDI, IPDI, and OXA. The SI values in the auricular LNs were much higher than those in the mandibular LNs. No increases in SI values in auricular LNs were seen following inhalation exposure to TMA, PA, or to FA, trimeric IPDI, and MS (Table 4 and Fig. 2 ). The auricular LNs following DNCB exposure, unfortunately, were not measured. Although the cervicalis posterior LNs seemed to be enlarged following exposure to HDI and IPDI, low SI values of about 3 ± 2 were observed, indicating borderline stimulation (data not shown).
The SIs of the positive controls (dermal exposure) are indicated in Table 5 . The SI values in the auricular LNs were very high. This was due to the concentrations tested that were generally much higher than EC 3 values of several of these compounds (Van Och et al., 2000) to minimize test failure. There was some variation in controls that were carried out twice (TMA, DNCB; Table 5 ). For some of the compounds, the negative control had a high tritium uptake resulting in lower SI values for the test groups and positive control. This is why the SI value for the auricular LNs following dermal exposure to TDI (positive control) is low in comparison to HDI and IPDI, whereas absolute tritium uptake was similar in these groups (Table 4) .
To investigate possible differences in sensitizing potency between routes of exposure, ED 3 values following inhalation exposure were compared to EC 3 values obtained following dermal exposure. The total dose by inhalation (3 days) was calculated and compared to that obtained by dermal application for 3 days. The total inhalation dose was calculated using the mean actual concentration (mg/m 3 ), the duration of exposure (min) at which an SI value of 3 was obtained, the mean body weight between day 0 and day 5 (g), and a standard ventilation rate of 1.5 l/kg for mice. The total dose by dermal application (3 days) was calculated using the applied volume (25 ll per ear) based on published EC 3 values for five of the tested compounds by Van Och et al. (2000) . Absorption was assumed to be 100% for both routes. With regard to potency ranking (Table 6 ), the dermal ranking would be: OXA, DNCB, diisocyanates, acid anhydrides, whereas the potency ranking following inhalation exposure is different: diisocyanates/OXA, acid anhydrides, DNCB. Interestingly, the contact allergens were as potent as the respiratory allergens to sensitize via the respiratory tract, as EC 3 and ED 3 values (assuming 100% absorption) were of the same order of magnitude regardless the exposure route (the maximum difference was a factor 10 in the case of PA, whereas OXA showed no difference at all).
Airway histopathology.
Trimeric IPDI was the only compound that did not induce histopathological lesions in the respiratory tract following exposure for 360 min/day. All other compounds induced lesions in the nasal tissues, and five of these also induced lesions in the larynx. No histopathological changes were observed in the lungs (Table 7) . Only at a very high concentration of 250 mg/m 3 TMA, which was used during preliminary testing to examine which LNs should be collected, histopathological changes were observed in the lungs. These changes consisted of slight mononuclear cell infiltrate (data not shown).
Severe lesions in the nasal tissues were induced by OXA and TDI, whereas HDI and IPDI induced moderate lesions in the nasal tissues. DNCB, PA, and FA were slightly to moderately, and TMA and MS were only slightly toxic to the nasal tissues. The concentrations used for the different compounds varied to some extent, and therefore, compounds could not be compared fully on the basis of the severity of the lesions. The changes consisted of inflammatory cell infiltration, epithelial degeneration, hyperplasia, and, in severe cases, ulceration. Exudative rhinitis was seen in all animals exposed to TDI and in three out of six animals exposed to IPDI. DNCB and OXA were also moderately toxic to the larynx, whereas One outlier was detected using Grubb's test and rejected for further analysis.
TMA, PA, and TDI induced only slight to moderate laryngeal lesions (Table 7) . The histopathological changes in nasal tissue and larynx induced by DNCB were exposure duration-related (Table 8) .
DISCUSSION
The LLNA in rodents is used as a test for predicting skin sensitization potential of compounds in humans. A chemical Results are expressed in means ± SEM. Solid line indicates an SI value of 3. Statistical analysis was performed after logarithmic transformation, using a one-way ANOVA followed by a two-sided Dunnett's t-test; *p < 0.05, **p < 0.005, ***p < 0.001.
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that induces a proliferation index (SI) of 3 or more in the ear draining (auricular) LNs is regarded a sensitizer. In the present study, all allergens, including the respiratory allergens, were tested positive following dermal application. Therefore, the present results support the view (Arts, 2001; Kimber et al., 2007; Van Loveren et al., 2008) that the skin LLNA can also detect respiratory sensitizers.
In analogy to the skin LLNA, a respiratory LLNA (exposure by inhalation) was developed, and cellular proliferation was determined in the respiratory tract draining LNs. Also in analogy to the skin LLNA, we hypothesized that a chemical that induced an SI of 3 or more in the respiratory tract draining LNs should be regarded a respiratory tract sensitizer.
The first challenge encountered in the respiratory LLNA was the identification of the LNs to be harvested. In contrast to the skin LLNA, in which the auricular LNs are the draining LNs, there are several groups of LNs draining the respiratory tract ( Van den Broeck et al., 2006) . However, the mandibular LNs turned out to be the LNs that were always grossly enlarged upon inhalation exposure, despite the different physicochemical characteristics of the allergens tested. This may be explained by a distance-related decrease in amounts of test material deposited in the respiratory tract following inhalation exposure. This assumption is supported by the results of the histopathological examination of the respiratory tract (Tables 7  and 8) , showing most effects on the nasal tissues. In addition, allergic rhinitis almost always precedes asthma, indicating that also in humans allergens predominantly impact on the upper respiratory tract tissues (Gautrin et al., 2006; Malo, 2005) . Therefore, it is advised to investigate the mandibular LNs in the respiratory LLNA, when testing compounds of unknown sensitizing potential.
Interestingly, inhalation exposure to the vapors TDI, HDI, IPDI, and the nebulized OXA following dissolution in acetone stimulated the auricular LNs as well, inducing even higher SI values in the auricular than in the mandibular LNs. The mandibular LNs drain on the posterior cervical LNs and not on the auricular LNs, and more distant LNs are not expected to show higher responses than LNs closer to the route of exposure. This was not observed in the case of TMA and PA. Therefore, it was concluded that head/nose-only exposure to the diisocyanates and OXA is very effective for uptake of the allergen via the skin, most probably via the sparsely haired ears. This may be (partly) due to the higher lipophilicity of the diisocyanates when compared to the acid anhydrides, viz. the predicted octanol-water partition coefficients (mean ± SD; using online software: http://www.vcclab.org/lab/alogps) are 1.13 ± 0.46, 1.35 ± 0.45, 2.40 ± 1.31, 2.73 ± 1.54, 3.31 ± 1.64 for TMA, PA, HDI, TDI, and IPDI, respectively. An experimental logP of 1.60 was reported for PA by Hansch et al. (1995) . The predicted logP for OXA is somewhere in between, viz. 2.03 ± 0.46.
Another problem was how to design an efficient and costeffective exposure regime in a respiratory LLNA suitable for investigating dose-response relationships. It was expected that the total dose per unit area rather than the concentration would be critical for sensitization (Gerberick et al., 2001; Menné and Calvin, 1993; White et al., 1986) . Therefore, duration rather than concentration was varied, viz. groups of animals were exposed for 3 days to a fixed concentration during different periods of time. Using this procedure, dose-response relationships were not always linear, but sometimes bell-shaped (Fig. 1) . It remains to be investigated whether this is due to the variation in duration rather than concentration.
All allergens, including DNCB and OXA, but except FA induced lymphocyte proliferation in the mandibular LNs (Table 3 and Fig. 1) . FA is considered an allergen of rather modest potency by some (Andersen et al., 1985 (Andersen et al., , 1995 Arts et al., 1997; Hilton et al., 1998) , which was also confirmed in the present study following dermal application, but relatively potent by others (Frankild et al., 2000) . In a range of compounds, EC 3 values varied from 0.01% for OXA to about 44% for isoprobyl myristate, whereas the EC 3 value for FA was reported to be 0.4% (Basketter et al., 2002) . De Jong et al. (2007) observed an EC 3 value for FA of 0.9%. In our study, a relative high dermal concentration of 10% FA induced an SI value of only 10 in the auricular LNs, which was low in comparison to most of the other allergens. The inhalation concentration of 3 ppm (3.6 mg/m 3 ) was considered slightly irritating, based on the induction of slight nasal respiratory Results are expressed in means ± SEM. Solid line indicates an SI value of 3. Statistical analysis was performed after logarithmic transformation, using a one-way ANOVA followed by a two-sided Dunnett's t-test; *p < 0.05, **p < 0.005, ***p < 0.001.
epithelial hyper/metaplasia following repeated exposure (reviewed by Arts et al., 2006) and the nasal squamous hyper/metaplasia in three out of six mice following exposure for 360 min/day for 3 days in the present study (Table 7) . However, although this concentration was irritating to the respiratory tract, it may still have been insufficient to induce sensitization. It could also mean that for moderately strong sensitizers, aerosolization rather than evaporation would be required to obtain sufficiently high concentrations in the respiratory tract.
The compound of unknown sensitizing potential trimeric IPDI was negative in the respiratory and skin LLNA. This may indicate that trimeric IPDI is a nonsensitizer. This is in accordance to the finding that the biuret or isocyanurate type homopolymers of HDI, unlike its monomeric form, did not induce sensitization by intradermal injection or via repeated inhalation exposures (Pauluhn et al., 2002) . On the other hand, the concentrations used in the present study might still have been too low, although trimeric IPDI was tested at a higher concentration than monomeric IPDI both via inhalation and dermal application. Trimeric IPDI (IPDI isocyanurate) was also negative in the Buehler test (Zissu et al., 1998) . However, it was tested at an induction concentration of 10% only, whereas other polyisocyanate prepolymers, viz. those of TDI and HDI, were concomitantly tested at much higher induction levels (30, 50, or 100%) and were found positive. Nonetheless, this means that these polyisocyanate prepolymers appear to be far less potent allergens than their monomeric counterparts.
The potency ranking in the respiratory LLNA differed from that in the skin LLNA. The typical respiratory allergens (the diisocyanates and the acid anhydrides) were more potent than DNCB via inhalation; the typical contact allergens OXA and DNCB were the most potent following dermal exposure. OXA was very potent via both routes, which supported our observation that OXA induced respiratory allergy in the Brown Norway rat model (Mommers et al., 2006) , besides the wellknown skin allergy (Asherson et al., 1983; De Sousa and Parrott, 1969; Kimber and Weisenberger, 1989; Parrott and De Sousa, 1966) .
The total dose calculated to induce an SI of 3 (assuming 100% absorption) was, therefore, slightly lower in the skin than in the respiratory tract for DNCB, similar in the skin and in the respiratory tract for OXA; and lower in the respiratory tract than in the skin for TMA, PA, and TDI. The maximum difference was a factor 10 in the case of PA (Table 6) .
SI values in the auricular LNs following dermal exposure were generally much higher (up to 415; Table 5 ) than the SI values in the mandibular LNs following inhalation exposure (up to 11; Fig. 1 ). This is most likely due to the higher amount of chemical that can be applied to the skin versus the airways as the presently tested inhalation concentrations already induced histopathological changes at various degrees (Tables 7  and 8 ). In addition, the total dose that reached the airway epithelium may have been much lower due to the altered breathing frequency and pattern induced by the allergeninduced irritation to the respiratory epithelium, thereby significantly reducing the calculated respiratory ED 3 values that assumed a normal breathing rate and 100% absorption (Table 6 ). Evidence of this is presented by animals that had air in the gastrointestinal tract suggestive of extensive irritation Three additional control animals were exposed to 1% DNCB (SI ¼ 61 ± 3.5). Three additional control animals were exposed to 1% DNCB (SI ¼ 15 ± 3.9). Note. The total dose by inhalation (3 days) was calculated using the mean actual concentration (mg/m 3 ), the interpolated (in some cases the extrapolated) duration of exposure (min) at which an SI value of 3 was obtained, the mean body weight between day 0 and day 5 (g), and a ventilation rate of 1.5 l/kg for mice. The total dose by dermal application (3 days) was calculated using the applied volume (25 ll per ear) based on published EC 3 values by Van Och et al. (2000) . Absorption was assumed to be 100% for both routes. FA, trimeric IPDI, and MS were negative and therefore not included in this Table. For the dermal route, an EC 3 value of 0.40% FA was reported by Basketter et al. (2002) and 0.9% FA by De Jong et al. (2007) .
RESPIRATORY LOCAL LYMPH NODE ASSAY and partial mouth breathing for ventilation. In addition, it is known that in mice under normal breathing conditions, the deposition of aerosol particles of about 2 micron MMAD may be approximately 50% in the nasal region and an additional 15-20% in the lower airways. Therefore, when the data are presented as EC 3 or ED 3 values (Table 6 ), viz. expressed in terms of delivered dose, the respiratory LLNA seems to be more sensitive than the traditional assay in view of the most probably much lower absorption value than 100% in the respiratory tract as described above. This may have important implication for risk assessment purposes.
In summary, the present results show that the respiratory LLNA can detect allergens. The respiratory LLNA can be used to test if a compound can sensitize the body via the respiratory tract, at what concentrations, and under which conditions. It may especially be used in case of highly volatile chemicals. Overall, in analogy to the dermal LLNA, the present results suggest that moderate to strong LMW allergens, regardless their immunological nature, cannot only sensitize the body via the skin but also via the respiratory tract. In addition, the contact allergens tested were as potent as the respiratory allergens to sensitize via the respiratory tract, which may pose a risk for human health if these compounds are inhaled. 
